Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$0.43 USD
-0.03 (-7.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.45 +0.02 (4.58%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ATHA 0.43 -0.03(-7.44%)
Will ATHA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATHA
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Other News for ATHA
Athira Pharma just downgraded at Mizuho, here's why
Hold Rating on Athira Pharma Amid Strategic Pivot and Clinical Uncertainty
Athira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical Progress
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70%